Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Up to 54 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Zinc and Copper; Drug
Lead sponsor: Phoenix Neurological Associates, LTD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Heart Block AV
Interventions: Medtronic Micra AV Device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Cancer
Interventions: Ability to order FirstLook™, Continuing Medical Education for Lung Cancer; Diagnostic Test · Other
Lead sponsor: Delfi Diagnostics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Jacksonville, Florida • Durham, North Carolina

Conditions: Substance Use, Stress, Relation, Interpersonal, Bullying, Victimisation, Mental Health Issue, Sleep, Inadequate, Social Skills
Interventions: PeerLearning.net; Behavioral
Lead sponsor: Oregon Research Behavioral Intervention Strategies, Inc.; Industry
Eligibility: Not listed
Enrollment: 924 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Eosinophilic Asthma
Interventions: ICS-LABA, benralizumab, Placebo for Benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more

Conditions: Type 2 Diabetes
Interventions: Whole Fruit; Other
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Li-Fraumeni Syndrome, Hereditary Cancer Syndromes, TP53 Gene Germline Mutation Carrier
Interventions: Not listed
Lead sponsor: Scripps Health; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 280
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more

Conditions: Prostate Cancer
Interventions: Apalutamide, Leuprolide, Prednisone, Abiraterone Acetate; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 4
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York

Conditions: Cardiovascular Disease, Type 2 Diabetes
Interventions: Pistachio; Other
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Cervical Dysfunction
Interventions: Cranial Vault Hold, Cervical HVLA; Procedure
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Major Depressive Disorder, Overweight, Inflammation
Interventions: Placebo, EPA 1 g/day, EPA 2 g/day, EPA 4 g/day; Other · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere); Drug · Combination Product
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Sacramento, California • Celebration, Florida • Miami, Florida + 10 more

Conditions: Acute Myeloid Leukemia
Interventions: peg-IFN-α, Hematopoietic Cell Transplant (HCT), Tacrolimus, Methotrexate; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Focal Therapy; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma
Interventions: PHOX2B PC-CAR T Cells; Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 1 Year and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
Interventions: Diagnostic tests for anal cancer screening; Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 35 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: New York, New York • Charleston, South Carolina • Houston, Texas

Conditions: Bloodloss, Surgical Procedures, Operative
Interventions: Ecallantide, Cyklokapron(R); Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Psychosis, Prodromal Schizophrenia, Prodromal Symptoms
Interventions: SCORES (Specific COgnitive Remediation with Support); Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 14 Years to 20 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Heart Failure
Interventions: Clinical Reminder; Other
Lead sponsor: VA Palo Alto Health Care System; Federal
Eligibility: 18 Years to 120 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms, Adenocarcinoma
Interventions: Gemcitabine, nab-paclitaxel, Pharmacological ascorbate; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Depression
Interventions: Cognitive behavior therapy (CBT), Supportive/expressive (S/E) therapy, Bibliotherapy; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 14 Years to 18 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Parkinson's Disease, Essential Tremor
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Aurora, Colorado

Search by objective public record fields.

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Safety Study of High Doses of Zinc in ALS Patients

Micra AV Tracking During Exercise Testing

Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer

Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Effects of Whole Fruit on Blood Sugar in People With Type 2 Diabetes

Biomarker Monitoring in TP53 Mutation Carriers

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Effects of Pistachios on Cardiovascular Responses to Stress in Type 2 Diabetes

Palpatory and Ultrasound Assessment of Cervical Dysfunctions and the Effect of Cervical High Velocity Low Amplitude (HVLA) Technique

Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Focal Therapy for Localized Prostate Cancer

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Screening Women With Prior HPV for Anal Neoplasia

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

Provider Notification for High B-type Natriuretic Peptide Values

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

Depression Prevention Program for Adolescents

Optimizing DBS Electrode Placement and Programming